Marker Therapeutics, Inc.
MRKR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 99.1% | -5.8% | 183% | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -104.3% | -214.6% | -240.6% | -154.7% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -168.7% | -356.1% | -483.9% | -3,118% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -162.8% | -248.8% | -851.9% | -3,372.7% |
| EPS Diluted | -1.19 | -1.93 | -3.58 | -5.47 |
| % Growth | 38.3% | 46.1% | 34.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |